Lawyers for Todd Engel, 62, filed suit yesterday in New Jersey superior court. According to the complaint, Engel is now ...

As the pharmaceutical industry continues to push the boundaries of innovation, the role of digital solutions like eCOA platforms will only grow in significance. For rare disease trials, where patient ...

Penpulimab has picked up a pair of approvals in nasopharyngeal carcinoma (NPC), becoming only the second drug to be cleared ...

Despite being on the US market since 1989 – initially for medical uses like strabismus and blepharospasm, and later for ...

Northwestern University spinout Grove Biopharma, a synthetic biology specialist developing a platform known as Bionic ...

In its first-quarter results update, MSD – which is known as Merck & Co in the US and Canada – said it expects full-year ...

So far, SpringWorks – which was spun out of Pfizer in 2017 and has recently received FDA approval for a second therapy for a ...

Across all industries, generative AI has become the latest buzz word. Talk of implementing automation and AI solutions to enhance human capacity continues to dominate conversations. In fact ...

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...

In another inflection point for the psychedelic medicines category, Mind Medicine (MindMed) has claimed breakthrough status from the FDA for its LSD-based candidate MM120 as a treatment for anxiety.

Each person living with a rare disease has a unique experience of their condition, but all will have faced similar challenges. They have suffered from an overwhelming diagnosis experience that has ...

Google gave an update on various aspects of its health-related R&D at its annual event The Check Up, including a new collection of artificial intelligence (AI) models intended to support drug ...